Genor Biopharma, a Pre-commercial Stage Biopharma Company, Announced the Appointment of Jack Hu as Chief Financial Officer and Chief Strategy Officer
SHANGHAI--(BUSINESS WIRE)-- Before joining Genor, Dr. Hu served as Managing Director and Head of APAC Healthcare Research at Deutsche Bank, where he covered Asia/China healthcare. Dr. Hu joined Deutsche Bank in 2010 and was ranked No.1 for All-China healthcare research by Institutional Investor magazine from 2015 to 2017. As a seasoned healthcare professional with deep knowledge of the biotech sector, Dr. Hu has nearly 20 years of experience working in equity research, hedge funds and multinational biopharmaceutical companies. Dr. Hu received a Ph.D. in molecular genetics from the M.D. Anderson Cancer Center and began his career at Wyeth (now part of Pfizer). He also covered the US biotech sector as a senior biotech analyst with Oppenheimer.
"I believe Dr. Hu’s extensive expertise will help Genor realize its vision of offering innovative, best-in class therapies to serve unmet patient needs. Dr. Hu’s deep knowledge of the healthcare industry and expertise in the financial and capital markets make him a vital addition to Genor’s talented leadership,” said Michael Xu, CEO of Genor, “Dr. Hu joins us at an important inflection point as our business becomes more global. We are excited to work with Dr. Hu in continuing to build strong corporate partnerships and our strategic financial capabilities,” added Mr. Xu.
"I am excited to join Genor, a firm that is committed to bringing life changing therapeutics to patients. I look forward to working with this dynamic team to create value for shareholders.” Dr. Hu commented.
About Genor Biopharma
Genor Biopharma is a clinical-stage biopharmaceutical company located in Zhangjiang, Shanghai, China. Genor is focused on the therapeutic areas of oncology and autoimmune diseases. The Company delivers a portfolio of novel therapies built to address unmet medical needs. The Company’s leading product candidates are late stage innovative monoclonal antibodies. Genor maintains state-of-the-art manufacturing facilities with cGMP capabilities in both Shanghai and Yunnan.
Source: Genor Biopharma